GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Q2FY27 Revenue up 37% YoY to ₹5,162m, EBITDA up 53%

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 27 Oct 2026, 10:46 AM IST  ·  BSE ID: 5886bb34-dd63-4e54-a2ec-6d921e180873
View Original BSE Filing (PDF)
💡
In Simple Terms
Onesource Specialty Pharma reported significantly higher sales and profits in the latest quarter due to new manufacturing capacity and product launches.
🤖 AI Summary
  • Onesource Specialty Pharma reported Q2FY27 consolidated revenue of ₹5,162m, an increase of 37% YoY.
  • EBITDA for Q2FY27 was ₹1,633m, reflecting a 53% YoY growth, with margins expanding to 31.6%.
  • Adjusted PAT for Q2FY27 stood at ₹937m, up 109% YoY, leading to an Adjusted EPS of ₹8.2.
  • Performance was attributed to new Drug-Device Combination (DDC) capacity, MSA execution, and 12 new product launches.
  • Operational highlights include commercialization of the second cartridge line and onboarding a new US biotech partner.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenues
₹5,162m
37%
EBITDA
₹1,633m
53%
EBITDA %
31.6%
329bps
Adjusted PAT
₹937m
109%
Adjusted EPS
₹8.2
109%
🏢 How This Affects the Company
📈
Business Impact
The company's revenue growth is driven by new DDC capacity, strong MSA execution, and 12 new product launches across all business segments. Onboarding a new US biotech partner for integrated DS + DP programs strengthens the biologics business momentum.
💰
Financial Impact
Revenue increased by 37% YoY to ₹5,162m, and EBITDA expanded by 53% YoY to ₹1,633m, indicating improved operational efficiency. EBITDA margins increased to 31.6% from 28.3% YoY, due to operating leverage from higher volumes.
⚙️
Operational Impact
The commercialization of the second cartridge line and completion of FAT for line 3 enhances DDC manufacturing capacity. This new capacity is expected to support new launches and a significant ramp-up in commercial volumes in H2 FY27.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected as the company's Q2FY27 financial performance shows significant growth in revenue, EBITDA, and Adjusted PAT.
🔍
Management Signal
The focus on new DDC capacity, MSA execution, and strategic partnerships, including a new US biotech partner, indicates management's intent for sustained growth and capacity expansion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — assess sustained revenue and EBITDA growth from new DDC capacity.
Updates on new product launches and impact on financial performance.
Further details on biologics partnerships and pipeline expansion.
LOW RISK The filing indicates strong financial performance and operational expansion with new capacities.
💡 Investor Takeaway
Onesource Specialty Pharma reported Q2FY27 consolidated revenue of ₹5,162m, up 37% YoY, and EBITDA of ₹1,633m, up 53% YoY. Adjusted PAT increased 109% YoY to ₹937m. Growth was driven by new DDC capacity, strong MSA execution, and 12 product launches.
⚖️ Strengths & Concerns

✅ Positives

  • Revenue grew 37% YoY to ₹5,162m, driven by new DDC capacity, MSA execution, and multiple product launches.
  • EBITDA increased 53% YoY to ₹1,633m, with margins expanding by 329bps YoY to 31.6%, due to operating leverage.
📅 Company Track Record
Onesource Specialty Pharma has consistently reported strong performance in recent periods, with Q4 FY26 revenue up 47% QoQ to ₹4,282 million and EBITDA expanding over 5x to ₹919 million. Q2 FY27 standalone Profit After Tax increased to Rs. 861.92 Million, up 132.32% YoY.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Onesource Specialty Pharma's Q2FY27 consolidated revenue?
Onesource Specialty Pharma's consolidated revenue for Q2FY27 was ₹5,162m, which is a 37% increase year-over-year.
What was Onesource Specialty Pharma's EBITDA for Q2FY27?
The company's EBITDA for Q2FY27 stood at ₹1,633m, representing a 53% increase from Q2FY26. EBITDA margins expanded to 31.6%.
How did Adjusted PAT perform for Onesource Specialty Pharma in Q2FY27?
Adjusted PAT for Q2FY27 was ₹937m, showing a 109% increase compared to Q2FY26. The Adjusted EPS was ₹8.2.
What factors drove Onesource Specialty Pharma's Q2FY27 performance?
The Q2FY27 performance was driven by new DDC capacity, strong MSA execution, and multiple product launches across all business segments.
What operational updates did Onesource Specialty Pharma announce in Q2FY27?
Onesource Specialty Pharma commercialized its second cartridge line and completed Factory Acceptance Test (FAT) for line 3, indicating enhanced DDC capacity.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.